The Week Ahead: Fed...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$0.92 -0.01 | -1.06%
06/04/12 - 03:56 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -12.52M | -18.39M | -10.36M | -11.83M |
| Operating Gains/Losses | -161.81K | 1.35M | -83.35K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 87.75K | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 888.25K | 213.57K | 243.66K | 249.00K |
| (Decrease) Increase In Other Current Liabilities | 129.44K | -67.61K | 423.71K | 0.00 |
| (Increase) Decrease In Other Working Capital | -14.52K | -327.29K | -2.74K | -10.00K |
| Other Non-Cash Items | 3.33M | 7.15M | 4.56M | 4.67M |
| Net Cash From Continuing Operations | -8.10M | -9.98M | -5.14M | -6.86M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.10M | -9.98M | -5.14M | -6.86M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -480.85K | -332.68K | -210.78K | -194.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -480.85K | -332.68K | -210.78K | -194.00K |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.67M | 17.27M | 2.76M | 4.55M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 1.67M | 17.27M | 2.76M | 4.55M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -6.91M | 6.95M | -2.59M | -2.50M |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- UserMy Folly
- ContributorStem Cell Stocks
- UserRAPTOR SPRTD-0902092107
- UserBlogue's Picks
- Userbrownmark68 Portfolio 1
- UserBENIRANS II
- UserEnergy and Options
Latest CUR Headlines from TheStreet
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
- Wednesday's Health Winners & Losers 09.19.07 | 04:09 pm
Press Releases for CUR
- DiagnoCure To Host Q2 2012 Conference Call And Webcast - PR Newswire 05.30.12 | 07:05 am
- PCA3 Test Featured At American Urological Association Meeting - PR Newswire 05.25.12 | 07:05 am
- Neuralstem CEO To Present At The World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.21.12 | 09:05 am
- DiagnoCure Issues Statement On Acquisition Of Gen-Probe By Hologic - PR Newswire 05.01.12 | 12:05 pm
- Neuralstem ALS Stem Cell Trial Interim Results Reported In The Journal, STEM CELLS - PR Newswire 03.28.12 | 09:03 am
- Fourteenth Patient Dosed In Neuralstem ALS Stem Cell Trial - PR Newswire 03.07.12 | 09:03 am
- PROGENSA® PCA3 Featured At European Association Of Urology Congress In Paris - PR Newswire 02.29.12 | 04:02 pm
- FDA Approves Gen-Probe's PROGENSA® PCA3 Assay, First Urine-Based Molecular Test To Help Determine Need For Repeat Prostate Biopsies - PR Newswire 02.15.12 | 07:02 am
- Neuralstem Announces Closing Of $5.2-Million Registered Direct Offering - PR Newswire 02.14.12 | 11:02 am
- Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2012 - PR Newswire 02.08.12 | 09:02 am
Partner Headlines for CUR
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
- Neuralstem Loses $0.08/Share in Q2 - Seeking Alpha 08.11.11 | 09:08 am
- Zacks' Voice of the People highlights opportunities with Citigroup, Neuralstem, Primerica, PDL Biopharma - Press Releases - Zacks 04.28.10 | 09:04 am
- Data Mining - With Your OWN Spreadsheets - Voice of the People - Zacks 04.27.10 | 06:04 pm
